All News

Treatment with adjuvant pembrolizumab reduced the risk of disease recurrence or death versus observation in patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma.

"ICD-10-CM coding denials have been increasing across the country as payers continue to refine edits," write Jonathan Rubenstein, MD, and Mark Painter.

The study achieved 100% local control and cancer-specific mortality rates with stereotactic ablative body radiotherapy.

"Psychological factors often have an important role [in erectile dysfunction], and psychological treatment options are available that have been found to improve outcomes," said Mark S. Allen, PhD.

This is the largest prostate cancer study that examined the exome, according to the researchers, who believe their findings can potentially inform the makeup of panels used for genetic testing in prostate cancer.

"Results showed that more than two-thirds of these men were found to have positive Posluma scans, with a quarter of them having extrapelvic lesions," says Ashesh B. Jani, MD, MSEE, FASTRO.

Data showed that the proportion of Black patients referred for genomic testing increased from 19% to 58% after the implementation of the precision medicine navigator.

The phase 1/2 COMBAT study examining the novel theranostic 64Cu/67Cu-SAR-Bombesin.

The approval is supported by findings from the phase 2 PHYOX2 trial and interim data from the phase 3 PHYOX3 extension study.

Patients who underwent treatment with SBRT demonstrated a 5-year disease control rate of 96%, compared with 95% among patients who underwent conventionally fractionated radiation therapy.

In the survey, 81% of residents in their final year of training reported that they sometimes, often, or always experienced feelings of burnout during their training.

The positioning system would allow patients with cancer to undergo radiation therapy in an upright, seated position.

About 1 of every 5 patients with stage I seminoma relapses; however, “the level of evidence supporting the use of currently defined risk factors in decision making is low,” wrote lead author Thomas Wagner, MD, and coinvestigators.

The inclusion of iTind is reflected in a newly added statement on temporary implanted prostatic devices.

If replicated with further study, the finding potentially expands noninvasive fertility treatment options and may minimize the need for expensive reproductive technology, according to lead author Scott D. Lundy, MD, PhD, of Cleveland Clinic’s Department of Urology.

“Implementation of the most recent PI-RADS update did not improve the incongruence in prostate cancer grade assessment between MRI/ultrasound fusion targeted biopsy and surgery,” the authors wrote.

"It is the right time and I have been fortunate to have such great people to work with locally and nationally," a urologist writes.

"It is erdafitinib’s time to shine," says Arlene O. Siefker-Radtke, MD.

The findings suggest that drug therapies targeting the NOTCH1 gene may serve as an alternative treatment option for patients with kidney cancer in whom surgery is not recommended.

The PSE test was shown to improve the predictive accuracy of a standard PSA test from 55% to 94%.

The reimbursement code for flotufolastat F 18 will be effective October 1, 2023.

“A hybrid telehealth approach expands access to specialized care, reduces travel burdens, promotes timely interventions, and enables continuous management of health conditions,” writes Kara Hartl, MD.

The addition of SBRT to upfront abiraterone acetate and prednisone (AAP) reduced the risk of disease progression or death by 65% compared with AAP alone in patients with oligometastatic castration-resistant prostate cancer.

“[These] results imply that prostate cancer survival could be improved, especially in historically under-served groups, by improving the timeliness of access to medical care," says Sean Clouston, PhD.

"At some point, it will make sense, and it will be obvious to me and to my colleagues that it is time," a urologist writes.

UCSF is West Coast leader for the innovative, minimally invasive treatment for prostate cancer patients.

The EV-302 trial is the confirmatory trial for the FDA’s accelerated approval of pembrolizumab plus enfortumab vedotin for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma.

"We all need to revisit meaningful methods for ongoing assurance of competency specific to our fields of medicine and surgery across the physician career span," writes Hal H. Atkinson, MD, MS.